Recombinant DNA Advisory Committee - 12/1-2/94 
Donna Huggins, NIDDK 
Christine Ireland, OD 
Becky Ann Lawson, OD 
Harry Malech, NIAID 
Catherine McKeon, NIDDK 
Hiroaki Mizukami, NHLBI 
David Nelson, NCHGR 
Tadatsugu Sato, NHLBI 
Thomas Shih, OD 
Debra Wilson, OD 
Others: 
Paul Aebersold, Food and Drug Administration 
Estuardo Aguilar-Cordova, Baylor College of Medicine 
Bob Anderson, Food and Drug Administration 
W. French Anderson, University of Southern California 
Dale Ando, Chiron Corporation 
Elizabeth Ashforth, Genetic Therapy, Inc. 
Greg Baigent, Chiron Corporation 
Peter Ballard, The Blue Sheet 
James Barrett, Genetic Therapy, Inc. 
Edward Beecham, Human Gene Therapy Research Institute 
Mitch Berger, University of Washington 
Bridget Binko, Cell Genesys 
John Bishop, Food and Drug Administration 
Ernst Boehnlein, Progenesys 
Arindam Bose, Pfizer, Inc. 
Rosemary Browar, Genetic Therapy, Inc. 
Jeff Carey, Genetic Therapy, Inc. 
Rachel Carle, Genzyme Corporation 
Ira Carmen, University of Illinois 
Mike Casey, Genetic Therapy, Inc. 
Joe Catino, Schering-Plough Corporation 
Yawen Chiang, Genetic Therapy, Inc. 
Kim Changmin, Korea Cancer Center Hospital 
Jan Chappell, Genetic Therapy, Inc. 
Shuhsia Chen, Baylor College of Medicine 
Theresa Chen, Genetic Therapy, Inc 
Tnjae Chung, MD Anderson Cancer Center 
Dorothy Clarke, Fox, Bennett and Turner 
Gary dayman, MD Anderson Cancer Center 
Kenneth Culver, Human Gene Therapy Research Institute 
John Cutt, Schering-Plough Corporation 
Karen Darcy, Magenta Corporation 
Eileen Deist, Genetic Therapy, Inc 
Boythe Devlin, Duke University 
Henry Dorkin, New England Medical Center 
Earl Dye, Food and Drug Administration 
Tom Eggerman, Food and Drug Administration 
Bryan Finkle, Canji, Inc 
Reinhard Fleer, Rhone-Poulenc Rorer 
Diane Fleming, Mid-Atlantic Biological Safety Association 
Remi Gloecker, Transgene, Inc 
Recombinant DNA Research, Volume 20 
[431] 
